Compare iShares MBS ETF (MBB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Organon & Co. Common Stock — how do they compare? iShares MBS ETF trades at $89.99 (market cap $35.58B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: iShares MBS ETF is far larger — about 9.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 97 Days and Organon & Co. Common Stock for 0 Days on average.
| MBB | OGN | |
|---|---|---|
Market Cap | $35.58B | $3.62B |
Volume | 3,918,815 | 2,892,999 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $13.81 |
52-Week Low | $89.09 | $5.70 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB trades at $90.00 with minimal daily movement (+0.19%). Technical indicators signal bearish momentum with RSI at overbought levels and moving averages trending downward. Recent news highlights significant short interest growth (98.3% increase in September 2026) and concerns about intermediate duration risk amid potential rate hikes. The ETF faces pressure from rising rates while maintaining consistent dividend distributions.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. While institutional buying provides some support, the combination of high short interest and duration risk creates headwinds. Investors should weigh the steady income against potential price depreciation in a rising rate environment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
